Teresa E Gambol

Learn More
PURPOSE To investigate changes in bone mineral density (BMD) and fracture risk in men who received intermittent androgen deprivation (IAD) for nonmetastatic, hormone-sensitive prostate cancer. PATIENTS AND METHODS Men with prostate cancer who lacked radiographically detectable metastases were treated in a prospective trial of IAD. After 9 months of(More)
When a physician decides on a treatment and its schedule for a specific patient, information gained from prior patients and experience in the past is taken into account. A more objective way to make such treatment decisions based on actual data would be useful to the clinician. Although there are many mathematical models proposed for various diseases, so(More)
99 Background: A recent phase III trial of intermittent vs. continuous AD supports IAD as standard of care for men treated with AD for BR. To identify potential factors during 1OFF prognostic for time to CRPC or PCM, relationships with times to T and PSA rises from our prospective trial of IAD in men with BR were analyzed. METHODS 72 patients were treated(More)
209 Background: Exisulind is an apoptotic drug shown in vitro to inhibit expression and function of the androgen receptor. At lower doses as a single agent and in combination with chemotherapy it has demonstrated limited efficacy. In this pilot study, the potential for high dose exisulind to prolong the duration of the off treatment interval of IAD was(More)
BACKGROUND Intermittent androgen deprivation (IAD) represents an alternative to continuous AD with quality-of-life benefit and no evidence of inferior overall survival for nonmetastatic prostate cancer. Early markers of prognosis for men treated with IAD have not been described. PATIENTS AND METHODS Men with nonmetastatic prostate cancer were treated with(More)
  • 1